Hyphens Pharma International Ltd. (SG:1J5) has released an update.
Hyphens Pharma International Ltd. has reported a significant financial performance boost in the first quarter of 2024, with a 44.4% increase in revenue and an impressive 97.6% rise in net profit after tax compared to the same period last year. Despite higher distribution and marketing costs, the company saw improved sales across all segments, especially in Specialty Pharma Principals. The firm continues to expand its Proprietary Brands through strategic partnerships, geographical market expansion, and product portfolio growth, despite a slight sales dip attributed to prior stock-up activities by distributors.
For further insights into SG:1J5 stock, check out TipRanks’ Stock Analysis page.
